8 results on '"Deng, Guangtong"'
Search Results
2. Ubiquitin‐specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling.
- Author
-
Sun, Huiyan, Meng, Yu, Yao, Lei, Du, Songtao, Li, Yayun, Zhou, Qian, Liu, Yihuang, Dian, Yating, Sun, Yuming, Wang, Xiaomin, Liang, Xiao‐wei, Deng, Guangtong, Chen, Xiang, and Zeng, Furong
- Subjects
DEUBIQUITINATING enzymes ,MELANOMA ,METASTASIS ,GENE silencing ,EPITHELIAL-mesenchymal transition ,DACARBAZINE - Abstract
Metastasis is a major contributing factor that affects the prognosis of melanoma patients. Nevertheless, the underlying molecular mechanisms involved in melanoma metastasis are not yet entirely understood. Here, we identified ubiquitin‐specific protease 22 (USP22) as a pro‐oncogenic protein in melanoma through screening the survival profiles of 52 ubiquitin‐specific proteases (USPs). USP22 demonstrates a strong association with poor clinical outcomes and is significantly overexpressed in melanoma. Ablation of USP22 expression remarkably attenuates melanoma migration, invasion, and epithelial–mesenchymal transition in vitro and suppresses melanoma metastasis in vivo. Mechanistically, USP22 controls melanoma metastasis through the SIRT1/PTEN/PI3K pathway. In addition, we conducted an United States Food and Drug Administration‐approved drug library screening and identified topotecan as a clinically applicable USP22‐targeting molecule by promoting proteasomal degradation of USP22. Finally, we found that both pharmacological and genetic silence of USP22 sensitize RSL3‐induced ferroptosis through suppressing the PI3K/Akt/mTOR pathway and its downstream SCD, and ferroptosis inhibitor could partly rescued the decreased lung metastasis by topotecan in vivo. Overall, our findings reveal a prometastatic role of USP22 and identify topotecan as a potent USP22‐targeting drug to limit melanoma metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies
- Author
-
Zhou, Qian, primary, Meng, Yu, additional, Li, Daishi, additional, Yao, Lei, additional, Le, Jiayuan, additional, Liu, Yihuang, additional, Sun, Yuming, additional, Zeng, Furong, additional, Chen, Xiang, additional, and Deng, Guangtong, additional
- Published
- 2024
- Full Text
- View/download PDF
4. The prevalence, complications, and risk factors for infantile hemangioma: a systematic review and meta‐analysis.
- Author
-
Sun, Yuming, Zhao, Jinhong, Meng, Yu, Luo, Xiangyue, Jiang, Chufeng, Deng, Guangtong, and Lei, Shaorong
- Subjects
HEMANGIOMAS ,PREGNANCY complications ,PREGNANT women ,SOCIOECONOMIC factors ,GLOBAL studies - Abstract
The epidemiological landscape of infantile hemangioma (IH) has been extensively explored through diverse data sources; however, a scarcity of systematically pooled and quantified evidence from comprehensive global studies persists. In this meta‐analysis, we systematically review available literature to elucidate the prevalence, distribution of lesions, complications, and risk factors associated with IH. A meticulous search encompassing the Cochrane Library, PubMed, Embase, and Web of Science identified 3206 records, of which 55 studies met the inclusion criteria. We found that the overall prevalence of IH is 2.8% [95% confidence interval (CI): 1.5–4.4%] (31,274,396 infants), and IH was located more frequently in the head and neck with a prevalence of 47.4% (95% CI: 39.5–55.4%). The overall prevalence of complications of IH is 24.3% (95% CI: 18.6–30.5%), ulceration is 16.0% (95% CI: 10.4–21.2%), bleeding is 5.6% (95% CI: 3.3–8.5%), visual impairment is 5.6% (95% CI: 3.0–8.9%), infection is 2.8% (95% CI: 1.5–4.8%), subglottic obstruction is 1.5% (95% CI: 0.5–3.0%), respectively. Through 27 studies, we have evaluated 35 factors encompassing perinatal factors, socioeconomic factors, maternal complications, drug factors, and antepartum procedures, and identified 18 risk factors that increase the prevalence of IH. These findings can greatly assist clinicians and family members in effectively evaluating the risk of IH, and determining whether pregnant women should undergo intensified monitoring or preventive measures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Predictors of survival in immunotherapy‐based treatments in advanced melanoma: a meta‐analysis.
- Author
-
Li, Daishi, Sun, Yuming, Le, Jiayuan, Dian, Yating, Liu, Yihuang, Zeng, Furong, Deng, Guangtong, Lei, Shaorong, and Su, Juan
- Subjects
- *
CLINICAL trials , *SKIN cancer , *RANDOMIZED controlled trials , *OVERALL survival , *MELANOMA - Abstract
The introduction of immunotherapy‐based strategies has significantly improved the prognosis for melanoma patients. Nevertheless, some patients still have dismal outcomes, emphasizing the significance of survival predictive indicators in immunotherapy‐based approaches. We systematically searched randomized controlled clinical trials investigating dual immunotherapy or chemoimmunotherapy versus placebo or mono‐immunotherapy or chemotherapy alone in advanced melanoma patients. R version 4.3.0. was employed to perform all analyses. A comprehensive analysis was conducted on a total of 13,809 patients with advanced melanoma from 19 randomized clinical trials. Immunotherapy‐based strategies (alone or in combination) could significantly lengthen the overall survival(OS) and recurrence‐free survival (RFS) compared with corresponding controls. Mono‐immunotherapy improved RFS and OS in PD‐L1 positive patients, in stage AJCC IIIC, and with 4 or more positive lymph nodes, compared with chemotherapy. Combined immunotherapy statistically improved RFS and OS in those aged < 65, with an Eastern Cooperative Oncology Group (ECOG) status of 0, and LDH ≤ ULN at baseline compared with single treatment alone. Our findings indicated that certain clinicopathological and molecular features could assist in choosing appropriate melanoma patients for immune‐based treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Molecular and therapeutic landscape of ferroptosis in skin diseases.
- Author
-
Le J, Meng Y, Wang Y, Li D, Zeng F, Xiong Y, Chen X, and Deng G
- Subjects
- Humans, Vitiligo metabolism, Vitiligo therapy, Lipid Peroxidation, Lupus Erythematosus, Systemic metabolism, Lupus Erythematosus, Systemic drug therapy, Iron metabolism, Psoriasis metabolism, Ferroptosis physiology, Skin Diseases metabolism
- Abstract
Abstract: Regulated cell death (RCD) is a critical physiological process essential in maintaining skin homeostasis. Among the various forms of RCD, ferroptosis stands out due to its distinct features of iron accumulation, lipid peroxidation, and involvement of various inhibitory antioxidant systems. In recent years, an expanding body of research has solidly linked ferroptosis to the emergence of skin disorders. Therefore, understanding the mechanisms underlying ferroptosis in skin diseases is crucial for advancing therapy and prevention strategies. This review commences with a succinct elucidation of the mechanisms that underpin ferroptosis, embarks on a thorough exploration of ferroptosis's role across a spectrum of skin conditions, encompassing melanoma, psoriasis, systemic lupus erythematosus (SLE), vitiligo, and dermatological ailments precipitated by ultraviolet (UV) exposure, and scrutinizes the potential therapeutic benefits of pharmacological interventions aimed at modulating ferroptosis for the amelioration of skin diseases., (Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.)
- Published
- 2024
- Full Text
- View/download PDF
7. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.
- Author
-
Sun Y, Liu Y, Dian Y, Zeng F, Deng G, and Lei S
- Subjects
- Humans, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic, Hypoglycemic Agents therapeutic use, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide-1 Receptor agonists, Glucagon-Like Peptide-1 Receptor genetics, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 genetics, Neoplasms genetics, Neoplasms epidemiology, Neoplasms drug therapy, Mendelian Randomization Analysis
- Abstract
Background: Glucagon-like peptide-1 receptor (GLP1R) agonists have been approved by Food and Drug Administration for management of obesity. However, the causal relationship of GLP1R agonists (GLP1RA) with cancers still unclear., Methods: The available cis-eQTLs for drugs target genes (GLP1R) were used as proxies for exposure to GLP1RA. Mendelian randomizations (MR) were performed to reveal the association of genetically-proxied GLP1RA with 14 common types cancer from large-scale consortia. Type 2 diabetes was used as positive control, and the GWASs data including 80 154 cases and 853 816 controls. Replicating the findings in the FinnGen study and then pooled with meta-analysis. Finally, all the related randomized controlled trails (RCTs) on GLP1RA were systematically searched from PubMed, Embase, and the Cochrane Library to comprehensively synthesize the evidence to validate any possible association with cancers., Result: A total of 22 significant cis-eQTL single-nucleotide polymorphisms were included as genetic instrument. The association of genetically-proxied GLP1RA with significantly decreased type 2 diabetes risk [OR (95%)=0.82 (0.79-0.86), P <0.001], which ensuring the effectiveness of identified genetic instruments. The authors found favorable evidence to support the association of GLP1RA with reduced breast cancer and basal cell carcinoma risk [0.92 (0.88-0.96), P <0.001, 0.92 (0.85-0.99), P =0.029, respectively], and with increased colorectal cancer risk [1.12 (1.07-1.18), P <0.001]. In addition, there was no suggestive evidence to support the association of GLP1RA with ovarian cancer [0.99 (0.90-1.09), P =0.827], lung cancer [1.01 (0.93-1.10), P =0760], and thyroid cancer [0.83 (0.63-1.10), P =0.187]. Our findings were consistent with the meta-analysis. Finally, 80 RCTs were included in the systematic review, with a low incidence of different kinds of cancer., Conclusions: Our study suggests that GLP1RA may decrease the risk of breast cancer and basal cell carcinoma, but increase the risk of colorectal cancer. However, according to the systematic review of RCTs, the incidence of cancer in patients treated with GLP1RA is low. Larger sample sizes of RCTs with long-term follow-up are necessary to establish the incidence of cancers and evaluate the risk-benefit ratios., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
8. Editorial: The impact of the COVID-19 pandemic on dermatology patients: diagnosis, treatment, and prognosis.
- Author
-
Huang H, Guo Z, Chen D, and Deng G
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.